Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (June 2023)
21 slides from Senseonics's investor presentation, June 2023
Slide 1: Eversense CGM System Corporate Presentation
Eversense ® CGM System The world’s FIRST and ONLY long-term Continuous Glucose Monitoring System Tim Goodnow, PhD Corporate Presentation President and CEO June 2023 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding managements plans, objectives and goals for future operations, expectations for future financial or other performance, stateme
Slide 3: Our Mission
OUR MISSION To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. 3
Slide 4: Corporate Overview and Milestones
CORPORATE OVERVIEW AND MILESTONES The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments. 2016 - 2017 2018 2019 2020 2021 2022 2023 Feb
Slide 5: High Growth Market
HIGH GROWTH MARKET CGM Fastest Growing Diabetes Technology Segment Globally* Global CGM Market Size $12.0 ~ 21% CAGR $11.0 $10.0 $14B+ Revenue in Billions ($) $9.5 $8.0 $8.1 Annual US $6.0 $7.1 Market $5.5 Opportunity $4.0 $4.2 $2.0 $0.0 *Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic
Slide 6: Significant Unmet Need Among BGM/CGM Users
SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS Why BGM users won't adopt CGM1 Most desired CGM improvements2 Longer Sensor Wear Better Accuracy 69% 73% 59% 34% 55% 40% 1 Market Segmentation Research June 2019 6 2 dQ&A CGM US Patient Survey Q3 2022
Slide 7: Eversense CGM System Addresses Unmet Needs as the First and Only
Eversense CGM System addresses unmet needs as THE FIRST AND ONLY ▪ CGM that lasts for 6 months vs. days ▪ Fully implantable 3rd generation sensor ▪ CGM achieves 8.5% MARD* ▪ Transmitter that is removable ▪ System with on-body vibe alerts for hypo and hyper warnings ▪ System with fresh, gentle-on ski
Slide 8: Eversense US Patient Profiles
1 EVERSENSE US PATIENT PROFILES Broad appeal of Eversense with new and existing CGM users Over 2/3 of our US patients switched from Usage split evenly across New Users by Diabetes Type other CGM solutions² age groups 24% 28% 21% New CGM User 19% 20% Type 1 16% 35% Type 2 Type 1 Type 2 52% 48% 72% Sw
Slide 9: Proven Top-Tier Accuracy in PROMISE Study
1 PROVEN TOP-TIER ACCURACY IN PROMISE STUDY Exceptional Performance for Duration of 180 Days MARD: 8.5% Accurate and stable for 6 months Highly accurate – Percent of readings within 15 mg/dL or 15% of particularly in low range reference value Percent of readings within 15 mg/dL or Prospective multi-
Slide 10: Strong and Expanding Reimbursement
STRONG AND EXPANDING REIMBURSEMENT Recent UnitedHealthcare coverage decision, expands access to approximately 300 million lives Strong adoption of 180-day payment across commercial payers CMS Calendar Year 2023 Medicare Physician Fee Schedule initiated updates to national pricing that accounts for t
Slide 11: Commercial Collaboration with Ascensia
COMMERCIAL COLLABORATION WITH ASCENSIA ▪ Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM ▪ ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense ®, Eversense® XL, Eversense® E3 and Future Generation Products ▪ Senseonics to Focus Str
Slide 12: Comprehensive Commercial Strategy
COMPREHENSIVE COMMERCIAL STRATEGY FOCUS ON INCREASING AWARENESS AND ACCESS TO EVERSENSE Prescribers and Geographic Direct to Consumer Geographic Inserters Focus Marketing Focus US: 230 active certified US: 50 dedicated sales >1,000,000 unique visitors to inserters and 680 prescribers people generati
Slide 13: Partnership with the Nurse Practitioner Group
PARTNERSHIP WITH THE NURSE PRACTITIONER GROUP Designate and train NPG certified inserters in key geographies to create convenient option for patient access • Network of 10,000+ healthcare professionals • NPs, MDs, PAs, Clinical Psychologists, RNs, MAs, etc. • 35 states and 50 cities • Women led – Mi
Slide 14: Eversense Pipeline
EVERSENSE PIPELINE 14
Slide 15: Product Vision
PRODUCT VISION Uniquely differentiated long-term technology solution with multiple product configurations with AID and Smart Pen integration SENSOR All Diabetes Patient Segments NO sensor change for 1 year NO daily calibration required NO transmitter on body For Type 1 and Type 2 Patients On Demand
Slide 16: Portfolio Overview
PORTFOLIO OVERVIEW 2022 2023 2024 2025 Connectivity 180-day Sensor iCGM Updates Approval BGM Connectivity Direct communication Pivotal Trial iCGM data will be 365-day Sensor Initiated available for analysis with Bluetooth Submit to FDA enabled blood glucose meters Gemini Complete Gemini Pump Integra
Slide 17: Eversense 365 System
EVERSENSE 365 SYSTEM One annual sensor for use – CGM for peace of mind and FGM for discretion TECHNOLOGY Gen 2 sensor (Rome); array-based sensing USE CASE Full year use with 1 sensor and 1 cal/week TARGET Intensively managed patients who want better control + All insulin-using patients PROGRESS Full
Slide 18: Gemini System
GEMINI SYSTEM Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform TECHNOLOGY Enhanced ROME2 sensor with integrated battery; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week Two unique products: • CGM with • Standalone transmitter therapeut
Slide 19: Freedom System
9 FREEDOM SYSTEM Elimination of Transmitter by incorporating BLE in the Sensor TECHNOLOGY Enhanced ROME2 sensor with integrated battery and BLE communication; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week No transmitter included in the System Direct communication between sens
Slide 20: Eversense Continuous Glucose Monitoring System
ae “e\/ersense. Continuous Glucose Monitoring System “ACCURATE. CONVENIENT. LIFE-CHANGIN e€Versense. Continuous Glucose Monitoring System 20
Slide 21: Thank You
THANK YOU 21
Senseonics Holdings — Investor Presentation (June 2023) on 6ix